IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (Nasdaq: ABEO) concerning possible violations of federal securities laws.
If you purchased shares of Abeona and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
Mako Research released a report on SeekingAlpha.com stating “ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure.” The report stated that Steven H. Rouhandeh, the Company’s Executive Chairman and Principal Executive Officer, was once the managing director at D. Blech & Co., a brokerage firm that was the subject of SEC investigations during the 1990s as well as a securities class action suit that ended in a $15 million investor settlement due to claims that the firm altered the price of some biotech stocks through transactions that falsely inflated the market price of the stocks to maintain the firm’s interest in these stocks. When this information was released to the public, the value of Abeona shares fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.